Laboratory of Intracellular Parasites, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, Montana, United States of America.
PLoS Pathog. 2010 May 27;6(5):e1000921. doi: 10.1371/journal.ppat.1000921.
Protection against virulent pathogens that cause acute, fatal disease is often hampered by development of microbial resistance to traditional chemotherapeutics. Further, most successful pathogens possess an array of immune evasion strategies to avoid detection and elimination by the host. Development of novel, immunomodulatory prophylaxes that target the host immune system, rather than the invading microbe, could serve as effective alternatives to traditional chemotherapies. Here we describe the development and mechanism of a novel pan-anti-bacterial prophylaxis. Using cationic liposome non-coding DNA complexes (CLDC) mixed with crude F. tularensis membrane protein fractions (MPF), we demonstrate control of virulent F. tularensis infection in vitro and in vivo. CLDC+MPF inhibited bacterial replication in primary human and murine macrophages in vitro. Control of infection in macrophages was mediated by both reactive nitrogen species (RNS) and reactive oxygen species (ROS) in mouse cells, and ROS in human cells. Importantly, mice treated with CLDC+MPF 3 days prior to challenge survived lethal intranasal infection with virulent F. tularensis. Similarly to in vitro observations, in vivo protection was dependent on the presence of RNS and ROS. Lastly, CLDC+MPF was also effective at controlling infections with Yersinia pestis, Burkholderia pseudomallei and Brucella abortus. Thus, CLDC+MPF represents a novel prophylaxis to protect against multiple, highly virulent pathogens.
针对导致急性、致命疾病的烈性病原体的保护常常受到微生物对传统化疗药物产生耐药性的阻碍。此外,大多数成功的病原体拥有一系列免疫逃避策略,以避免被宿主检测和消除。开发针对宿主免疫系统而非入侵微生物的新型免疫调节性预防措施,可以作为传统化疗的有效替代方法。在这里,我们描述了一种新型广谱抗细菌预防措施的开发和机制。我们使用阳离子脂质体非编码 DNA 复合物 (CLDC) 与粗制土拉弗朗西斯菌膜蛋白部分 (MPF) 混合,证明了其在体外和体内控制烈性土拉弗朗西斯菌感染的能力。CLDC+MPF 在体外抑制了原代人源和鼠源巨噬细胞中的细菌复制。在小鼠细胞中,感染的控制是通过活性氮 (RNS) 和活性氧 (ROS) 介导的,而在人源细胞中则是通过 ROS 介导的。重要的是,在挑战前 3 天用 CLDC+MPF 处理的小鼠能够存活致命的鼻内烈性土拉弗朗西斯菌感染。与体外观察结果相似,体内保护依赖于 RNS 和 ROS 的存在。最后,CLDC+MPF 还能有效控制鼠疫耶尔森菌、鼻疽伯克霍尔德菌和流产布鲁氏菌的感染。因此,CLDC+MPF 代表了一种针对多种高致病性病原体的新型预防措施。